



Announcement no. 19/2007

To OMX the Nordic Exchange

Copenhagen, July 6, 2007

Total share capital and total number of votes in Curalogic A/S

Under section 17(2) of Executive Order no. 226 of 15 March 2007 on the disclosure requirements of issuers, we hereby announce that, as of today, Curalogic A/S' share capital totals DKK 28,214,408 divided into 56,428,816 shares of DKK 0.50 corresponding to 56,428,816 voting rights.

Yours sincerely,

Curalogic A/S

For additional information, please contact:

Peter Moldt, President and CEO, Phone +45 33 11 41 01, mobile +45 26 25 04 22
Helle Busck Fensvig, EVP and CFO, Phone +45 33 11 41 01, mobile +45 20 70 55 37

About Curalogic

Curalogic is a Danish biopharmaceutical company listed on the OMX Nordic Exchange (CUR.CO). Curalogic develops innovative pharmaceuticals for the treatment of allergy. By combining the best of two worlds - the efficacy of immunotherapy combined with the safety and patient convenience of symptomatic treatments – Curalogic aims to develop a novel and user-friendly form of allergy treatment, and make it the preferred type of allergy treatment among patients. Curalogic has a broad and mature pipeline with a product for treatment of ragweed allergy in Phase III, a product for treatment of grass allergy ready for Phase III, a product for treatment of cat allergy in Phase II and a product for treatment of house dust mite allergy preparing for clinical trials.